Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry

Basit Öğe Kaydı
dc.authorid0000-0002-4124-1586en_US
dc.contributor.authorBodur, Hatice
dc.contributor.authorYurdakul, Fatma Gül
dc.contributor.authorAtaman, Şebnem
dc.contributor.authorÇay, Hasan Fatih
dc.contributor.authorGürer, Gülcan
dc.contributor.authorÇapkın, Erhan
dc.contributor.authorÇevik, Remzi
dc.date.accessioned2023-03-27T11:44:05Z
dc.date.available2023-03-27T11:44:05Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Fizik Tedavi ve Rehabilitasyon Ana Bilim Dalıen_US
dc.description.abstractObjectives Factors associated with disease activity of axial spondyloarthritis (axSpA) and switching of biologic disease-modifying anti-rheumatic drugs have not been clearly defined. We aimed to evaluate clinical characteristics of patients with axSpA, factors related to remission in treat to target era and predictive factors for biologic disease-modifying anti-rheumatic drug switching. Method A multicenter, observational cross-sectional study was performed between February 2019 and August 2019. We included all consecutive patients >= 18 years with axSpA. Demographic and clinical variables were prospectively recorded. Clinical tools included Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Metrology Index (BASMI), and Maastricht Ankylosing Spondylitis Enthesitis Score (MASES). Results There were 969 patients with a mean age of 43.4 +/- 10.8 years. There were 143 patients (14.8%) with remission and 223 (23.1%) patients with low disease activity. Male sex (p = 0.021), positive family history (p = 0.036), and human leukocyte antigen-B27 (p = 0.011) were predictors of remission by ASDAS-CRP. There were 654 patients (67.5%) who did not switch to another drug. The highest BASMI and MASES scores were calculated in patients with very high disease activity (p < 0.05). In patients with drug switching, the disease duration was significantly higher (p < 0.001) and the age at diagnosis was significantly lower (p = 0.016). There were significantly more patients with uveitis and higher scores of MASES and BASMI in patients who switch to another biologic disease-modifying anti-rheumatic drugs (p = 0 .003, p = 0 .009, and p = 0.004, respectively). Conclusions In patients with axSpA, male sex, younger age, and HLA-B27 positivity are associated with remission, while longer disease duration and accompanied uveitis appear to be related with drug switching.en_US
dc.identifier.citationBodur, H., Yurdakul, F.G., Ataman, Ş., Çay, H.F., Gürer, G., Çapkın, E. ve diğerleri. (2022). Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry. Clinical Rheumatology, 41(7), 2053-2063.en_US
dc.identifier.doi10.1007/s10067-022-06145-8
dc.identifier.endpage2063en_US
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue7en_US
dc.identifier.pmid35353263
dc.identifier.scopus2-s2.0-85127446841
dc.identifier.scopusqualityQ1
dc.identifier.startpage2053en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s10067-022-06145-8
dc.identifier.urihttps://hdl.handle.net/11468/11527
dc.identifier.volume41en_US
dc.identifier.wosWOS:000775708600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÇevik, Remzi
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofClinical Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDisease modifying anti rheumatic drugsen_US
dc.subjectDrug switchingen_US
dc.subjectRemission inductionen_US
dc.subjectSpondyloarthritisen_US
dc.titleWhere we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registryen_US
dc.titleWhere we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Where we are in treat to target era.pdf
Boyut:
828.65 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu